10.02.17
JAPAN: Kyocera subsidiary Kyocera Communication Systems Co., Ltd. (KCCS) has started joint research with the University of Tsukuba to develop an artificial intelligence (AI) system capable of detecting melanoma and other skin diseases by analyzing digital images of a patient’s skin. The team aims to commercialize the technology by 2020.
KCCS is working with two professors from the Department of Dermatology at the University of Tsukubato to develop an image-recognition system accurate enough to distinguish several types of skin malignancies, including melanoma. The next phase of their project will aim for image-based diagnostic support of any skin disease.
The project benefits from a database of more than 200 clinical images accumulated over 20 years by the University of Tsukuba Hospital’s Department of Dermatology. The University’s experiences and knowledge including these images will be instrumental in assessing image-based diagnostic accuracy in real-world conditions, said KCCS.
KCCS and the University of Tsukuba began conducting joint research in March and it will continue for a year. With the goal of commercial application by March 2020. Furthermore, the two organizations plan to develop a digital imaging system capable of identifying more than 2,000 different skin diseases.
KCCS is working with two professors from the Department of Dermatology at the University of Tsukubato to develop an image-recognition system accurate enough to distinguish several types of skin malignancies, including melanoma. The next phase of their project will aim for image-based diagnostic support of any skin disease.
The project benefits from a database of more than 200 clinical images accumulated over 20 years by the University of Tsukuba Hospital’s Department of Dermatology. The University’s experiences and knowledge including these images will be instrumental in assessing image-based diagnostic accuracy in real-world conditions, said KCCS.
KCCS and the University of Tsukuba began conducting joint research in March and it will continue for a year. With the goal of commercial application by March 2020. Furthermore, the two organizations plan to develop a digital imaging system capable of identifying more than 2,000 different skin diseases.